Tilray Brands, Inc. TLRY

Tilray Brands will announce its Q1 FY2027 financial results for the quarter ended August 31, 2026 before the market open on October 8, 2026, followed by a live conference call and audio webcast at 8:30 AM Eastern. The press release describes Tilray as a global lifestyle and consumer packaged goods company with operations across Canada, the United States, Europe, Australia and Latin America, offering cannabis, hemp-based foods and craft beverages across more than 40 brands in over 20 countries. It also provides media and investor contacts and notes that the webcast will be accessible via the Investor Relations site. Near-term sentiment and stock movement may be influenced by the earnings release timing, but no fundamental strategic changes are announced.

Tilray Brands has fallen about 56% year-to-date and roughly 96.7% over five years, even as it diversifies beyond cannabis and reports operating improvements. In Q4 fiscal 2026 (year ended May 31), revenue reached a record $915.5 million, up 11%, with gross profit up 8% and adjusted EBITDA rising to $61.1 million from $55 million. Recreational cannabis accounts for less than a third of sales; alcohol, medical cannabis distribution, and wellness drive growth. However, ongoing share dilution remains a major headwind, with shares rising from 116.5 million to 136.2 million between Jan 6 and July 26. Tilray also holds $235 million in cash and a near debt-free balance sheet, plus potential upside from partnerships like Carlsberg-branded beer licensing in the US. Guidance calls for $1 billion in revenue and higher EBITDA, but GAAP profitability remains elusive and the stock’s dilution clouds the outlook. Motley Fool notes Tilray wasn’t among its picks. Ongoing share dilution undermines profitability and investor sentiment, offset by cash reserves and potential partnerships.

Tilray Brands, Inc. now owns BrewDog and launches a major multi-platform campaign to signal a new era of investment, energy and growth. The push follows nearly £50 million in capital injected since the acquisition, with BrewDog pledging renewed investment in its brand, people, bars and Scottish brewing heritage. The 'Under New Ownership' campaign, debuting Sept. 21, includes large-format outdoor, digital screens and a 70,000-copy City AM letter from Tilray, plus activations across supermarkets, on-trade and BrewDog bars to drive footfall and sales. BrewDog leadership emphasizes a return to momentum, supported by partnerships (Underbelly, Leicester Tigers) and an expanded bar/platform strategy that now features Tilray-owned American craft beers in BrewDog venues. Awards won in 2026 bolster credibility as the company restarts growth with broader distribution, seasonal promotions and consumer-facing offers. Large-scale investment and a bold, multi-channel rebranding campaign under Tilray ownership are likely to meaningfully shift BrewDog’s growth trajectory and investor sentiment.

Tilray Brands' takeover of BrewDog is being promoted in a first campaign that distances BrewDog from its previous owners. The Scottish craft brewer, acquired in March for £33 million after going into administration, says ads will feature less controversy and no more stunts. Tilray has invested about £50 million to stabilise BrewDog, relaunch 16 bars and launch new beers. BrewDog faced 2021 staff allegations about culture, prompting co-founders James Watt and Martin Dickie to apologise and for an independent review. The new campaign highlights being 'under new ownership' and a 'people-first' approach, with a letter promising to take care of the business. The insolvency period saw 38 bars close and 484 jobs lost, but Tilray aims to re-energise BrewDog and grow the brand globally. Significant expansion of Tilray's consumer brand portfolio with a capital infusion and rebranding push aimed at stabilizing and growing BrewDog in Europe.

Tilray Brands, Inc. (TLRY) closed at $4.08, up 2.26% and outperforming the S&P 500's 1.49% gain as markets rose. The stock has fallen 17.56% over the past month, underperforming the Medical sector and the S&P 500's modest gains. Investors await Tilray's upcoming earnings release; consensus projects revenue of about $268.23 million, up 28.03% year over year. For the full year, Zacks Consensus estimates call for a loss of $0.42 per share on $1.1 billion in revenue, implying substantial revenue growth but continued negative earnings. Zacks notes that revisions to estimates can influence near-term price action, and Tilray carries a Zacks Rank of #3 (Hold) within the Medical - Products industry, which sits in the top half of its sector. Upcoming earnings release and consensus revisions could nudge near-term sentiment, but no major catalysts are indicated.

Tilray Brands, Inc. (TLRY) is down over 55% in 2026. The upcoming midterm elections and cannabis-reform chatter could spark a short-term rally, as reform news tends to lift cannabis names in the near term. However, the piece notes reform is a long, drawn-out process and any gains are unlikely to be durable without stronger fundamentals. Tilray remains highly volatile, with rallies historically short-lived. The Motley Fool mentions that Tilray isn’t among its top 10 stock picks and cautions investors that the stock’s volatility and lack of solid fundamentals limit upside. Short-term, sentiment-driven upside from reform talk and elections, but weak fundamentals limit lasting impact.

Trump's marijuana rescheduling push regains focus, prompting questions on whether Tilray stock is now a buy. Potential marijuana rescheduling could significantly boost Tilray's operations and stock trajectory.

Tilray Brands posts record fiscal revenue yet trades below $5 with unclear factors suppressing the stock. Record revenue fails to lift shares above $5 highlighting persistent market concerns.

TLRY shares see fading gains from cannabis rescheduling hopes amid concerns over potential Washington delays. Regulatory uncertainty around cannabis rescheduling continues to weigh on Tilray's market performance and investor outlook.

BrewDog launches Liquid Visions craft beer series targeted at retail shelves. New beverage product series may moderately support market positioning in drinks category.

Tilray Brands reported record fiscal 2026 revenue yet its stock showed no rally in response. Record revenue failed to lift stock price pointing to investor doubts on long-term growth.

Tilray Brands boosts medical cannabis production capacity to meet surging international demand and reinforce its global leadership position. Major production increase directly supports revenue growth and market share gains in expanding international medical cannabis markets.

Tilray Medical acknowledges advancements in Germany's medical cannabis regulations while endorsing further policy enhancements. German regulatory improvements position Tilray for expanded medical cannabis operations in Europe.

Tilray Medical launches branded cannabis medicines direct to UK patients via Lyphe Clinic and Lyphe Dispensary, accelerating commercial expansion. UK direct-to-patient rollout adds European sales channel with moderate revenue upside.

Tilray Brands expects to reach $1 billion in annual revenue this fiscal year via targeted growth strategies. Revenue milestone of $1 billion signals major growth trajectory for Tilray Brands.

Tilray Brands launches Mollo Lite, drawing fresh attention and sparking debate over the company's valuation. Mollo Lite launch marks a significant product introduction likely to shift Tilray's market position and investor sentiment.

Tilray Brands launches Mollo Lite Blackberry Lemon Seltzer Multi-Pack to expand THC beverage innovation. New product extends THC beverage line with incremental consumer option.

GTBIF stock receives buy, hold or sell analysis after Tilray Brands Q2 earnings release. Q2 earnings and related stock recommendation moderately affect Tilray Brands investor sentiment and short-term performance.

Tilray Brands saw most of its growth last year come from an unexpected part of its operations rather than core cannabis activities. Unexpected growth driver points to possible revenue diversification that could moderately support future results.

Jefferies states Tilray Brands creates long-term value through its diversified platform. Analyst view on diversification points to moderate effects on valuation and sentiment without major operational shifts.

Tilray Brands Inc posted record revenue in Q4 2026 earnings call alongside strategic updates. Record revenue from earnings call signals strong performance likely to shift investor sentiment and company trajectory.

Tilray Brands reported Q4 2026 results during its earnings call, covering revenue, losses, segment performance in cannabis and beverages, and forward guidance. Earnings releases and guidance updates deliver financial metrics that moderately shift near-term sentiment and valuation.

Tilray Brands Q4 earnings call highlights financial results, revenue figures, operational updates and forward guidance for the cannabis company. Q4 earnings and guidance directly shape near-term financial outlook and investor positioning for TLRY.

Tilray Brands achieved record fiscal 2026 revenue and adjusted EBITDA via its diversified global platform in cannabis, beverage, hospitality and wellness. Record revenue and EBITDA figures point to major positive shifts in Tilray's financial trajectory and market sentiment.

Tilray Brands launches ZONNA THC pouches for cannabis consumers. New THC pouch launch expands Tilray product line and targets core cannabis market growth.

TLRY stock faces buy decision ahead of July 28 catalyst that could shift near-term price action and investor positioning. July 28 date introduces potential catalyst that may moderately affect short-term trading and sentiment around TLRY.

Tilray Medical commercially launches medical cannabis in Panama to expand patient access across Latin America. Panama launch adds moderate Latin American revenue potential without transforming overall trajectory.

Tilray Brands acquires HelloMD Corporation, gaining telemedicine capabilities, medical cannabis patient access, and expanded market reach in Canada and beyond. Acquisition adds telemedicine platform and patient network that moderately strengthens Tilray's medical cannabis operations.

Tilray Brands plans strategic medical cannabis expansion. Strategic medical cannabis expansion represents a major move likely to alter Tilray's growth trajectory and investor sentiment.

Tilray Brands acquires HelloMD to strengthen its global medical cannabis platform and expand Canadian patient access. Acquisition expands Tilray's medical cannabis operations and Canadian market reach.